Cedra names two new directors

They join business development in generics and automation for the bioanalytical division

Cedra Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, has appointed John Pottier as senior director of business development in generics and Thomas Lloyd as director of automation for the Bioanalytical Group.

Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.

Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.

Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.

You may also like

Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Manufacturing

Accelerating self-administration and homecare with large-volume prefillable glass syringe

SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
Manufacturing

Aenova expands sterile fill & finish manufacturing at its Latina site

New line to boost biologics capacity and support a wide range of container formats
Research & Development

Certified biobased resins bring sustainable lab filtration to Cytiva’s customers

Certified materials enable labs to choose more sustainable options without changing workflows or compromising performance
Research & Development

Syngene International plans to add bioconjugation suite for end-to-end antibody-drug conjugates development

Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services
Research & Development

Cellarity unveils AI-driven framework for cell state-correcting drug discovery in the journal Science

Biotech innovator Cellarity publishes a breakthrough blueprint integrating multiomics and machine learning to accelerate discovery of complex disease therapies, alongside the release of three open-access single-cell datasets
Subscribe now